euHeart

Cardiovascular disease (CVD) has a significant impact on the European society in terms of mortality, morbidity and allied healthcare costs. The opportunity of multi-scale modelling spanning, sub-cellular level up to whole heart is to improve CVD outcomes by providing a consistent, biophysically-based framework for the integration of the huge amount of fragmented and inhomogeneous data currently available. However, multi-scale models have not yet been translated into clinical environments mainly due to the difficulty of personalising biophysical models. The challenge of the euHeart project is to directly address this need by combining novel ICT technologies with integrative multi-scale computational models of the heart in clinical environments to improve diagnosis, treatment planning and interventions for CVD.

To meet this challenge we will bring together leading European physiological modelling and cardiac groups to develop, integrate and clinically validate patient-specific computational models of the cardiac physiology and disease-related processes. The main outcome of euHeart will be an open source framework for the description and representation of normal and pathological multi-scale and multi-physics cardiovascular models, using the international encoding standards. In addition, a library of innovative tools for the execution of the biophysical simulations, the personalisation of the models and the automated analysis of multi-modal images are developed.

Evidence of clinical benefit will be collected to quantify potential impact for a number of significant CVD's namely, heart failure, cardiac rhythm disorder, coronary artery disease and valvular and aortic diseases. Each of the selected clinical applications provides a complementary focus for the resulting integrated model of cardiac fluid-electro-mechanical function. The consortium contains a mix of academic leadership, clinical sites, and industrial partners ensuring exploitation of the wealth of models.

For further information, please visit:
http://www.euheart.org

Project co-ordinator:
Philips Technologie GmbH

Partners:

  • INRIA, Institut National de Recherche en Informatique et en Automatique
  • King's College London
  • Academisch Medisch Centrum bij de Universiteit van Amsterdam
  • Polydimensions GmbH
  • Universitat Pompeu Fabra
  • The University of Sheffield
  • Hospital Clinico San Carlos de Madrid Insalud
  • Philips Iberica S.A.
  • Institut National de la Santé et de la Recherche Médicale (INSERM)
  • Volcano Europe SA/NV
  • The Chancellor, Master and Scholars of the University of Oxford
  • HemoLab B.V.
  • Deutsche Krebsforschungszentrum (DKFZ)
  • Berlin Heart GmbH
  • Universität Karlsruhe (Technische Hochschule)
  • Philips Medical Systems Nederland BV

Timetable: from 06/2008 – to 05/2012

Total cost: € 19.053.465

EC funding: € 13.900.000

Programme Acronym: FP7-ICT

Subprogramme Area: Virtual physiological human

Contract type: Collaborative project (generic)


Related news article:

Most Popular Now

Free Online Tool Helps Determine Whether…

University of California, Irvine health sciences researchers have created a machine-learning model to predict the probability that a COVID-19 patient will need a ventilator or ICU care. The tool is...

Study Details First Artificial Intellige…

Hospital-based laboratories and doctors at the front line of the COVID-19 pandemic might soon add artificial intelligence to their testing toolkit. A recent study conducted with collaborators from the University...

Accelerating Data Solutions to Save LIVE…

The consortium of COVID-X announces the launch of the ​1st Open Call ​framed in a ​2-year initiative that will invest ​4 million € to fast-track to market 30+ European data...

Significant Disparities in Telemedicine …

After "COVID-19," the term that most people will remember best from 2020 is likely to be "social distancing." While it most commonly applied to social gatherings with family and friends...

Model Used to Evaluate Lockdowns was Fla…

In a recent study, researchers from Imperial College London developed a model to assess the effect of different measures used to curb the spread of the coronavirus. However, the model...

New Virtual Screening Strategy Identifie…

A novel computational drug screening strategy combined with lab experiments suggest that pralatrexate, a chemotherapy medication originally developed to treat lymphoma, could potentially be repurposed to treat COVID-19. Haiping Zhang...

Using Artificial Intelligence to Find Ne…

Scientists have developed a machine-learning method that crunches massive amounts of data to help determine which existing medications could improve outcomes in diseases for which they are not prescribed. The intent...

One in Four Doctors Attacked, Harassed o…

While many physicians benefit from social media by networking with potential collaborators or interfacing with patients, a new study from Northwestern University and the University of Chicago found many physicians...

CliniSys Launches Laboratory Information…

CliniSys has launched a new laboratory information management system for genomic laboratories in the UK. The company has brought GLIMS Genomics to the UK from Europe, where it is being...

The Institute of Healthcare Management C…

The Institute of Healthcare Management has called for honest and open communication about NHS capacity after a snapshot survey revealed the scale of sickness absence across the service. The UK's leading...